Glp-1 receptor agonists - Open Access .click

Results 261 to 270 of about 165,965 (304)

Some of the next articles are maybe not open access.

GLP-1 receptor agonists and vascular protection.

American Journal of Physiology. Heart and Circulatory Physiology
Atherosclerotic cardiovascular disease is a chronic condition that often co-presents with type 2 diabetes and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin mimetics endorsed by major professional societies for improving ...
B. Park +9 more
semanticscholar +1 more source

GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

Nature Communications
Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes.
Heng-Chih Pan +6 more
semanticscholar +1 more source

Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022
Hertzel Gerstein, Matthew Lee, Naveed Sattar +2 more
exaly

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Nature Reviews Endocrinology, 2012
J. Meier
semanticscholar +1 more source

Mapping the effectiveness and risks of GLP-1 receptor agonists

Nature Medicine
Yan Xie, Taeyoung Choi, Z. Al-Aly
semanticscholar +1 more source

GLP-1 receptor agonists and suicidality

BMJ
Peter, Ueda, Björn, Pasternak
openaire +2 more sources

The Future of the GLP-1 Receptor Agonists

JAMA, 2019
openaire +2 more sources

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes

Journal of Clinical Medicine, 2021
Andréea Ciudin, Ciudin Andréea
exaly